3-(4-methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine | 221539-63-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 3-(4-methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine
• 英文别名: 2,4-dioxo-3-(4-methoxybenzyl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine；3-[(4-methoxyphenyl)methyl]-1H-pyrido[2,3-d]pyrimidine-2,4-dione
• CAS: 221539-63-5
• 化学式: C₁₅H₁₃N₃O₃
• 分子量: 283.287
• InChiKey: CTFNUHAOXQQQLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine 以83%的产率得到1-(3-chloropropyl)-2,4-dioxo-3-(4-methoxybenzyl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine
  参考文献：
  名称：

  Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs

  摘要：

  一种由以下式表示的化合物：[其中环A代表一个可选具有取代基的同环或一个可选具有取代基的含氮杂环；D和E为O或S；R1和R2中的一个代表一个由以下式表示的基团：(其中Ar1和Ar2代表一个可选具有取代基的芳香族基团；Ar1和Ar2可以与相邻的碳原子一起形成一个可选具有取代基的紧邻环基团；环B代表一个可选具有取代基的含氮杂环；X和Y为键合，O，S(O)p (p为0到2的整数)，NR4 (R4为H或较低烷基基团)或一个双价的直链较低碳氢基团，其中可能含有1到3个杂原子，可选具有取代基；R3代表H，一个可选具有取代基的羟基或一个可选酯化的羧基)；另一个是氢原子、氰基或可选具有取代基的碳氢基团]，或其盐，具有抗组胺作用、抗炎作用、嗜酸性粒细胞趋化抑制作用，可用于预防或治疗哮喘、过敏性结膜炎、过敏性鼻炎、荨麻疹、特应性皮炎等。

  公开号：

  US06407116B1
• 作为产物：
  描述：

  N-(4-methoxyphenyl)methyl-2-aminonicotinic acid amide 以88%的产率得到3-(4-methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine
  参考文献：
  名称：

  Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs

  摘要：

  一种由以下式表示的化合物：[其中环A代表一个可选具有取代基的同环或一个可选具有取代基的含氮杂环；D和E为O或S；R1和R2中的一个代表一个由以下式表示的基团：(其中Ar1和Ar2代表一个可选具有取代基的芳香族基团；Ar1和Ar2可以与相邻的碳原子一起形成一个可选具有取代基的紧邻环基团；环B代表一个可选具有取代基的含氮杂环；X和Y为键合，O，S(O)p (p为0到2的整数)，NR4 (R4为H或较低烷基基团)或一个双价的直链较低碳氢基团，其中可能含有1到3个杂原子，可选具有取代基；R3代表H，一个可选具有取代基的羟基或一个可选酯化的羧基)；另一个是氢原子、氰基或可选具有取代基的碳氢基团]，或其盐，具有抗组胺作用、抗炎作用、嗜酸性粒细胞趋化抑制作用，可用于预防或治疗哮喘、过敏性结膜炎、过敏性鼻炎、荨麻疹、特应性皮炎等。

  公开号：

  US06407116B1

文献信息

• NITROGENOUS FUSED-RING COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME, AND DRUGS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1026160A1

  公开（公告）日：2000-08-09

  A compound represented by the formula: [wherein ring A represents a homocycle optionally having substituents or a nitrogen-containing heterocycle optionally having substituents; D and E are O or S; one of R1 and R2 represents a group represented by the formula: (wherein Ar1 and Ar2 represent an aromatic group optionally having substituents; Ar1 and Ar2 may form a condensed cyclic group optionally having substituents together with an adjacent carbon atom; ring B represents a nitrogen-containing heterocycle optionally having substituents; X and Y are a bond, O, S(O)p (p is an integer of 0 to 2), NR4 (R4 is H or a lower alkyl group) or a bivalent straight-chained lower hydrocarbon group, which may contain 1 to 3 hetero atoms, optionally having substituents; and R3 represents H, a hydroxy group optionally having substituents or an optionally esterified carboxyl group); and the other is a hydrogen atom, a cyano group or a hydrocarbon group optionally having substituents], or a salt thereof, has an anti-histaminic action, an anti-inflammatory action, eosinophil chemotaxis-inhibiting action, and is useful for preventing or treating asthma, allergic conjunctivitis, allergic rhinitis, urticaria, atopic dermatitis and so on.

  式所代表的化合物： [其中环 A 代表任选具有取代基的均环或任选具有取代基的含氮杂环；D 和 E 为 O 或 S；R1 和 R2 中的一个代表由式表示的基团： (其中 Ar1 和 Ar2 代表可选择具有取代基的芳香族基团；Ar1 和 Ar2 可与相邻碳原子一起形成可选择具有取代基的缩合环基；环 B 代表可选择具有取代基的含氮杂环；X 和 Y 是键、O、S(O)p(p 是 0 至 2 的整数)、NR4(R4 是 H 或低级烷基)或二价直链低级烃基，其中可包含 1 至 3 个杂原子，可选择具有取代基；和 R3 代表 H、可选择具有取代基的羟基或可选择酯化的羧基）；另一个是氢原子、氰基或可选择具有取代基的烃基]，或其盐，具有抗组胺作用、抗炎作用、抑制嗜酸性粒细胞趋化作用，可用于预防或治疗哮喘、过敏性结膜炎、过敏性鼻炎、荨麻疹、特应性皮炎等。
• Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model
  作者：Miriam Redondo、Juan G. Zarruk、Placido Ceballos、Daniel I. Pérez、Concepción Pérez、Ana Perez-Castillo、María A. Moro、José Brea、Cristina Val、María I. Cadavid、María I. Loza、Nuria E. Campillo、Ana Martínez、Carmen Gil

  DOI：10.1016/j.ejmech.2011.10.040

  日期：2012.1

  A simple and efficient synthetic method for the preparation of quinazoline type phosphodiesterase 7 (PDE7) inhibitors, based on microwave irradiation, has been developed. The use of this methodology improved yields and reaction times, providing a scalable procedure. These compounds are pharmacologically interesting because of their in vivo efficacy both in spinal cord injury and Parkinson's disease models, as shown in previous studies from our group. Herein we describe for the first time that administration of one of the PDE7 inhibitors here optimized, 3-pheny1-2,4-dithioxo-1,2,3,4-tetrahydroquinazoline (compound 5), ameliorated brain damage and improved behavioral outcome in a permanent middle cerebral artery occlusion (pMCAO) stroke model. Furthermore, we demonstrate that these PDE7 inhibitors are potent anti-inflammatory as well as neuroprotective agents in primary cultures of neural cells. These results led us to propose PDE7 inhibitors as a new class of therapeutic agents for neuroprotection. (C) 2011 Elsevier Masson SAS. All rights reserved.
• US6407116B1
  申请人：——

  公开号：US6407116B1

  公开（公告）日：2002-06-18
• Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
  申请人：Takeda Chemical Industries, Inc.

  公开号：US06407116B1

  公开（公告）日：2002-06-18

  A compound represented by the formula: [wherein ring A represents a homocycle optionally having substituents or a nitrogen-containing heterocycle optionally having substituents; D and E are O or S; one of R1 and R2 represents a group represented by the formula: (wherein Ar1 and Ar2 represent an aromatic group optionally having substituents; Ar1 and Ar2 may form a condensed cyclic group optionally having substituents together with an adjacent carbon atom; ring B represents a nitrogen-containing heterocycle optionally having substituents; X and Y are a bond, O, S(O)p (p is an integer of 0 to 2), NR4 (R4 is H or a lower alkyl group) or a bivalent straight-chained lower hydrocarbon group, which may contain 1 to 3 hetero atoms, optionally having substituents; and R3 represents H, a hydroxy group optionally having substituents or an optionally esterified carboxyl group); and the other is a hydrogen atom, a cyano group or a hydrocarbon group optionally having substituents], or a salt thereof, has an anti-histaminic action, an anti-inflammatory action, eosinophil chemotaxis-inhibiting action, and is useful for preventing or treating asthma, allergic conjunctivitis, allergic rhinitis, urticaria, atopic dermatitis and so on.

  一种由以下式表示的化合物：[其中环A代表一个可选具有取代基的同环或一个可选具有取代基的含氮杂环；D和E为O或S；R1和R2中的一个代表一个由以下式表示的基团：(其中Ar1和Ar2代表一个可选具有取代基的芳香族基团；Ar1和Ar2可以与相邻的碳原子一起形成一个可选具有取代基的紧邻环基团；环B代表一个可选具有取代基的含氮杂环；X和Y为键合，O，S(O)p (p为0到2的整数)，NR4 (R4为H或较低烷基基团)或一个双价的直链较低碳氢基团，其中可能含有1到3个杂原子，可选具有取代基；R3代表H，一个可选具有取代基的羟基或一个可选酯化的羧基)；另一个是氢原子、氰基或可选具有取代基的碳氢基团]，或其盐，具有抗组胺作用、抗炎作用、嗜酸性粒细胞趋化抑制作用，可用于预防或治疗哮喘、过敏性结膜炎、过敏性鼻炎、荨麻疹、特应性皮炎等。